Anna B. Halpern, MD
I enjoy the opportunity to develop deep, long-term relationships with you and your family as well as the exciting pace of the oncology field. Oncology is moving so fast, and we’re continually improving the treatment options we can offer you. There’s so much innovation in the way researchers approach the disease, from personalized regimens that target each cancer’s mutations to therapies that harness the body’s immune system. It inspires me as a clinician and as a researcher.
I work with you to design and implement a personalized plan of cancer care that balances your and your family’s needs, the characteristics of your disease and the leading-edge science and clinical trials offered at SCCA.
Specialty: Medical Oncology
I am both a hematologist-oncologist and a clinical researcher. Along with caring for you, I conduct research focused on hematologic (blood-based) malignancies — specifically, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), polycythemia vera, essential thrombocythemia and myelofibrosis. My overarching research aim is to help adults with these diseases have better outcomes by developing and testing evidence-based therapies that are tailored to your unique needs as a patient. I design and conduct clinical trials testing novel care concepts for people with AML and MDS, and I use large databases to study systems issues on a broader scale, such as risk factors for toxicities from treatment.
The initiation of intense induction chemotherapy for patients with Acute Myeloid Leukemia (AML) has traditionally required long inpatient admissions. These hospitalizations – lasting four to five weeks on average – have been accepted as the standard of care given the need for management of treatment-related cytopenia and the associated infectious and bleeding risks.
We make promising new treatments available to you through studies called clinical trials led by SCCA doctors. Many of these trials at SCCA have led to FDA-approved treatments and have improved standards of care globally. Together, you and your doctor can decide if a study is right for you.
Many of our SCCA physicians conduct ongoing research to improve standards of patient care. Their work is evaluated by other physicians and selected for publication to the United States National Library of Medicine, the largest medical library in the world. See scientific papers this SCCA provider has written.
SCCA providers are often asked to give their medical expertise for press and news publications. Read articles by or about this SCCA provider.
Key research spans CAR T-cell therapies and treatments for myeloma, leukemia and more.
Your care team
SCCA accepts most national private health insurance plans as well as Medicare. We also accept Medicaid for people from Washington, Alaska, Montana and Idaho. We are working to ensure that everyone, no matter what their financial situation, has access to the care they need.